Delivery Order SPE2DB20D1100-SPE2DB25FE2D9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $19,905.32 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's substantial Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded contract employs firm fixed price pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. HUMIRA is a biologic medication commonly used...
- The Defense Logistics Agency awarded a $13,333.53 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this delivery order fulfills immediate pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,482.94 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on August 12, 2025, with completion targeted for August 13, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic immunosuppressant medication commonly prescribed for rheumatoid arthritis,...
- The Defense Logistics Agency awarded a delivery order valued at $1,394.58 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used to treat inflammatory conditions. The contract was awarded on August 19, 2025, with a completion date of August 20, 2025, and employs firm fixed price pricing with no set-aside designation. The product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,857.24 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,510.62 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 80 mg/0.8 mL on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used pharmaceutical for treating various autoimmune conditions and is a critical medical supply required...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE2D9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. HUMIRA is a widely prescribed immunosuppressant medication used to treat various autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical vendor within the federal medical supply chain. The company holds a $999,999,999.00 prime IDC with DLA Troop Support Medical (SPE2DX), valid through December 2026, which serves as the overarching vehicle enabling the delivery of comprehensive pharmaceutical products and medical supplies to military healthcare programs globally. AmerisourceBergen's federal contract portfolio demonstrates sustained capability to fulfill diverse medical procurement requirements across multiple therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible and competitively awarded contract mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 8/21/25 |